Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xilio Therapeutics ( (XLO) ) just unveiled an announcement.
On February 11, 2026, Xilio Therapeutics announced the pricing of an underwritten offering of pre-funded warrants to purchase 74,780,300 shares of common stock at $0.5349 per warrant, each exercisable at $0.0001 per share. The transaction, led by Leerink Partners as sole bookrunner, is expected to close on or about February 13, 2026, subject to customary closing conditions and exercise limitations that cap individual holders’ beneficial ownership.
The offering is expected to generate approximately $40 million in gross proceeds, or about $37.1 million in net proceeds after underwriting discounts, commissions and expenses, with Xilio planning to use the funds to advance its cancer drug pipeline and for general corporate purposes. Participation by existing backers Coastlands Capital and major healthcare investors including Gilead Sciences, OrbiMed and Perceptive Advisors underscores continued institutional support and provides Xilio with additional runway to execute its clinical strategy in a challenging biotech funding environment.
The most recent analyst rating on (XLO) stock is a Hold with a $0.59 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.
Spark’s Take on XLO Stock
According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.
The score is primarily held back by weak financial fundamentals (large losses, ongoing cash burn, and negative equity) despite strong recent revenue growth. Technicals are mixed with a weak longer-term trend but neutral-to-stable near-term momentum. Corporate events improve the outlook by extending cash runway into 2027, while valuation is constrained by a negative P/E and no dividend data.
To see Spark’s full report on XLO stock, click here.
More about Xilio Therapeutics
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies aimed at improving cancer treatment outcomes while reducing systemic side effects. Leveraging proprietary masking technology, the company is advancing a pipeline of novel immuno-oncology molecules designed to localize anti-tumor activity within the tumor microenvironment.
The company’s strategy targets patients living with cancer who may not tolerate or respond optimally to existing immuno-oncology therapies, positioning Xilio within a competitive but expanding segment of the oncology biotech market. Its emphasis on improving the therapeutic index of cancer drugs underscores a bid to differentiate its platform and attract long-term support from specialized life sciences investors.
Average Trading Volume: 483,423
Technical Sentiment Signal: Sell
Current Market Cap: $36.57M
For detailed information about XLO stock, go to TipRanks’ Stock Analysis page.